Literature DB >> 20073558

Inhalation adjuvant therapy for lung cancer.

Dandan Yi1, Timothy Scott Wiedmann.   

Abstract

BACKGROUND: Lung cancer is the leading cause of new cancer cases and also is the number one cause of cancer death in both male and females in the United States and the world. Lung cancer is histologically separated into either small-cell (SCLC) or nonsmall-cell lung cancer (NSCLC). NSCLC is much more common, and can occur in the periphery (adenocarcinomas) or central airways (squamous cell carcinomas).
METHODS: The literature pertaining to lung cancer adjuvant therapy and inhalation lung cancer chemoprevention was reviewed.
RESULTS: It is argued that inhalation of chemotherapy as an adjuvant in Stage II NSCC and inhalation of chemopreventive agents in Stage I adenocarcinomas are direct paths to improve lung cancer therapy as well as demonstrate the utility of inhalation therapy.
CONCLUSIONS: If successful, inhalation delivery may be extended to the treatment of other types of lung cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20073558     DOI: 10.1089/jamp.2009.0787

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  4 in total

1.  Pulmonary Delivery of Magnetically Targeted Nano-in-Microparticles.

Authors:  Amber A McBride; Dominique N Price; Pavan Muttil
Journal:  Methods Mol Biol       Date:  2017

2.  Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice.

Authors:  Donna E Seabloom; Arthur R Galbraith; Anna M Haynes; Jennifer D Antonides; Beverly R Wuertz; Wendy A Miller; Kimberly A Miller; Vernon E Steele; Chen S Suen; M Gerard O'Sullivan; Frank G Ondrey
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-19

3.  Enhancing therapeutic efficacy through designed aggregation of nanoparticles.

Authors:  Tanmoy Sadhukha; Timothy S Wiedmann; Jayanth Panyam
Journal:  Biomaterials       Date:  2014-06-16       Impact factor: 12.479

4.  Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations.

Authors:  Srinivas R B Behara; P Worth Longest; Dale R Farkas; Michael Hindle
Journal:  J Pharm Sci       Date:  2013-12-04       Impact factor: 3.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.